This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Secukinumab in multi-failure psoriatic patients: t...
Journal

Secukinumab in multi-failure psoriatic patients: the last hope?

Read time: 1 mins
Published:1st Sep 2018
Author: Magnano M, Loi C, Patrizi A, Sgubbi P, Balestri R, Rech G et al.
Availability: Pay for access, or by subscription
Ref.:J Dermatolog Treat. 2018 Sep;29(6):583-585.
DOI:10.1080/09546634.2018.1427206
Secukinumab in multi-failure psoriatic patients: the last hope?


Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.


Read abstract on library site    Access full article